Table 2.

Treatment and blinatumomab responses

	Before blinatumomab		After blinatumomab
	Treatment	MRD	Treatment	MRD
Case 1	VCR/pred × 2 wk	8% (predose escalation)	Low-dose oral mercaptopurine+IT Ara-C	Negative after cycle 2
Case 2	4 drug induction*	1.9%	Haploidentical BMT	Negative

Ara-C, cytosine arabinoside; BMT, bone marrow transplant; IT, intrathecal; pred, prednisone; VCR, vincristine.

^*4-drug induction, regimen B of UKALL2019 protocol.¹²